07/07/2026 Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy Turn Therapeutics announced the final stage 2 design and data-driven expansion of the GX-03 phase 2 trial in Atopic Dermatitis Everest Medicines announced the closing of its exclusive licencing agreement with Travere Therapeutics for civorebrutinib Vera Therapeutics announced US FDA accelerated approval of TRUTAKNA™ for adults with primary IgA nephropathy (R

30/03/2026 Aurinia Pharmaceuticals announced acquisition of Kezar Life Sciences Savara announced EMA validation of MAA for MOLBREEVI in autoimmune PAP Aurinia Pharmaceuticals announced acquisition of Kezar Life Sciences ( Ref ) Aurinia Pharmaceuticals entered into a definitive merger agreement to acquire Kezar life sciences for $6.955 per share in cash, plus one non-transferable Contingent Value Right (CVR), which represents the right to receive: Potential payments from the